Charles Schwab
ELDN icon

Charles Schwab’s Eledon Pharmaceuticals ELDN Stock Holding History

Charles Schwab’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$975K Buy
247,404
+53,382
+28% +$194K ﹤0.01% 3015
2026
Q1 		$598K Buy
194,022
+20,891
+12% +$49.2K ﹤0.01% 3051
2025
Q4 		$261K Buy
173,131
+10,289
+6% +$24.5K ﹤0.01% 3304
2025
Q3 		$422K Sell
162,842
-14,407
-8% -$42.1K ﹤0.01% 3219
2025
Q2 		$480K Buy
177,249
+147,262
+491% +$442K ﹤0.01% 3152
2025
Q1 		$102K Hold
29,987
– – ﹤0.01% 3340
2024
Q4 		$124K Buy
29,987
+15,000
+100% +$59.1K ﹤0.01% 3382
2024
Q3 		$37.3K Hold
14,987
– – ﹤0.01% 3442
2024
Q2 		$39.6K Hold
14,987
– – ﹤0.01% 3533
2024
Q1 		$30.9K Hold
14,987
– – ﹤0.01% 3410
2023
Q4 		$27K Hold
14,987
– – ﹤0.01% 3460
2023
Q3 		$20.5K Hold
14,987
– – ﹤0.01% 3512
2023
Q2 		$20.5K Hold
14,987
– – ﹤0.01% 3557
2023
Q1 		$35.4K Buy
+14,987
New +$40.2K ﹤0.01% 3417
2017
Q2 		– Sell
-93
Closed -$13K – 3111
2017
Q1 		$13K Hold
93
– – ﹤0.01% 3053
2016
Q4 		$15K Hold
93
– – ﹤0.01% 3074
2016
Q3 		$23K Hold
93
– – ﹤0.01% 3033
2016
Q2 		$83K Sell
93
-17
-15% -$18.8K ﹤0.01% 3068
2016
Q1 		$101K Hold
110
– – ﹤0.01% 2992
2015
Q4 		$157K Hold
110
– – ﹤0.01% 3002
2015
Q3 		$186K Buy
+110
New +$227K ﹤0.01% 2968

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Charles Schwab's ELDN Position: Q2 2026 in Review

Charles Schwab increased its Eledon Pharmaceuticals (ELDN) stake by 28% in Q2 2026, buying an estimated $194K and bringing the position to 247,404 shares worth $975K. The position accounts for ﹤0.01% of the portfolio, ranked #3015.

Charles Schwab first reported a position in ELDN in Q3 2015 and has held it in 21 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Charles Schwab held 247,404 shares of Eledon Pharmaceuticals worth $975K as of Q2 2026.
  • Charles Schwab bought 53,382 Eledon Pharmaceuticals shares in Q2 2026, an estimated $194K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3015 holding.
  • Charles Schwab first reported a position in Eledon Pharmaceuticals in Q3 2015 and has held it in 21 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.